Pacific Edge Ltd
NZX:PEB

Watchlist Manager
Pacific Edge Ltd Logo
Pacific Edge Ltd
NZX:PEB
Watchlist
Price: 0.114 NZD -7.32% Market Closed
Market Cap: 92.6m NZD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PEB stock under the Base Case scenario is 0.11 NZD. Compared to the current market price of 0.114 NZD, Pacific Edge Ltd is Overvalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PEB Relative Value
Base Case
0.11 NZD
Overvaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.3
P/S
P/S
Price to Sales
4.3
vs History
76
vs Industry
61
Median 3Y
5.1
Median 5Y
24.4
Industry
6.9
Forward
4.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-15.9
Industry
21.9
Forward
-3.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-25.4
Industry
18.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-21.6
Industry
23.8
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
73
vs Industry
34
Median 3Y
2.7
Median 5Y
4.2
Industry
2.3
More Details
2.7
EV/S
EV/S
Enterprise Value to Sales
2.7
vs History
73
vs Industry
59
Median 3Y
3.4
Median 5Y
18.1
Industry
7.1
Forward
2.9
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.7
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
28
Median 3Y
-2.4
Median 5Y
-9.7
Industry
3.6
Forward
-2.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
27
Median 3Y
-2.4
Median 5Y
-9.7
Industry
3.4
Forward
-1.9
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
30
Median 3Y
-3.2
Median 5Y
-18.2
Industry
4.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
27
Median 3Y
-3
Median 5Y
-17.5
Industry
2.8
More Details
7.3
EV/IC
EV/IC
Enterprise Value to IC
7.3
vs History
73
vs Industry
21
Median 3Y
9.2
Median 5Y
43.8
Industry
4.4
More Details

Multiples Across Competitors

PEB Competitors Multiples
Pacific Edge Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
Pacific Edge Ltd
NZX:PEB
92.6m NZD 4.3 -3.2 -1.9 -1.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 908 997.7 -165 917.3 -201 476.5 -199 177.4
US
Abbvie Inc
NYSE:ABBV
318.4B USD 5.7 75.1 15 22.6
US
Amgen Inc
NASDAQ:AMGN
150.2B USD 4.5 36.7 15.2 26.8
US
Gilead Sciences Inc
NASDAQ:GILD
132.3B USD 4.6 275.5 10.8 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.5B USD 11.5 -236.2 25.9 27.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 018.1 -515 -560.8 -545.8
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.7B USD 4.6 14.9 9.4 10.4
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -57.9
NL
argenx SE
XBRU:ARGX
32.4B EUR 16.8 44.2 -2 501.1 -1 676.9
P/S Multiple
Revenue Growth P/S to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average P/S: 3 173 735.6
4.3
-9%
N/A
FR
Pharnext SCA
OTC:PNEXF
34 908 997.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.5
10%
1.1
US
E
Epizyme Inc
F:EPE
2 018.1
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
7%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
16.8
37%
0.5
P/E Multiple
Earnings Growth PEG
NZ
Pacific Edge Ltd
NZX:PEB
Average P/E: 79
Negative Multiple: -3.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 917.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
75.1
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.7
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
275.5
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -236.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
44.2
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average EV/EBITDA: 15.5
Negative Multiple: -1.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 476.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 501.1 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
Pacific Edge Ltd
NZX:PEB
Average EV/EBIT: 20.3
Negative Multiple: -1.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 177.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.1
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -545.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 676.9 N/A N/A

See Also

Summary
PEB intrinsic value, competitors valuation, and company profile.
DCF Valuation
PEB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PEB stock valuation using valuation multiples.
Wall Street Estimates
PEB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PEB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 248,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.